O’n trafodaethau parhaus gyda Llywodraeth y DU a’r gwneuthurwyr, a dealltwriaeth o’r amodau ar gyfer cynnal treialon y brechlyn, rydym yn ymwybodol o’r heriau wrth storio, trin a dosbarthu’r brechlyn Pfizer/BioNTech. Yn benodol, y ffaith bod angen ei storio ar dymheredd isel iawn, o dan minws -75ºC +/- 15ºC. Pennwyd dau safle arbenigol fel safleoedd priodol i gadw’r brechlyn, ac fe fydd Byrddau Iechyd lleol yn casglu’r brechlynnau yn uniongyrchol o’r safleoedd hynny. Rydym wedi bod yn edrych ar opsiynau addas ar gyfer y camau cychwynnol wrth ddosbarthu’r brechlyn, yn unol â chyngor JCVI, gan gofio’r cyfyngiadau sy’n gysylltiedig â’i nodweddion a’r goblygiadau ar gyfer ei ddarparu i bob grŵp. Yn ymarferol ar hyn o bryd, ni allwn fynd â’r brechlyn hwn i gartrefi gofal.
From our ongoing discussions with UK Government and the manufacturer, and from understanding the conditions under which the vaccine trials have been conducted, we are aware of the challenges of storing, distributing and handling the Pfizer/BioNTech vaccine. In particular its need for storage at very low temperatures of below minus -75ºC +/- 15ºC.  Two specialist sites have been identified as appropriate delivery sites for the vaccine and local Health Boards will collect the vaccines directly from the two sites. We have been exploring suitable options for initial deployment of this vaccine, in line with the JCVI advice, bearing in mind the constraints associated its characteristics and the implications for delivery to all groups. In practical terms at this stage that we cannot deliver this vaccine to care homes.